Thanks for the kudos.
After having a private discussion with my bud Rick, I decided to start the thread not so much because I was in love with BLUE, but just thought that the timing was right for the immuno oncology targets and stocks. I have had a bit of time the past year or so to post. But then, earlier this year, it was obvious that the large cap biotech stocks like CELG, BIIB, REGN, and and a couple others were overvalued and there would be a biotech stock correction. That happened much like tulips that once fell out of favor, and BLUE came back down from its highs, having been halved in price. On Rick's thread, we did talk about the temporary end to the correction (most are temporary only, at least for a while!), and a few of us bottom fished.
These immuno oncology stocks will continue to be hot in my view. I also have finally realized that the anti-obesity stocks and companies have challenges in approvals/and or sales, but I did also sell OREX into the PDUFA date run-up, and then upon the announcement delay, I reloaded big time. Already great start to those shares.
By the way, did I mention that I thought BLUE was overvalued, at least it was at the open on Monday? |
